Multiplex white paper | Flexible biopharmaceutical manufacturing
A new white paper called "Manufacturing Injectables in the Multiplex" which describes a strategy for creating flexible and cost-effective biopharmaceutical manufacturing.

New white paper describes “Multiplex” strategy to achieve flexibility and scale in biopharmaceutical manufacturing

October 10, 2017 - Featured, White Paper

Vanrx Pharmasystems has released Manufacturing Injectables in the Multiplex, a white paper that describes a strategy to achieve flexibility and scale in biopharmaceutical manufacturing.

The white paper is available for download at

Multiplex manufacturing configures operations around smaller units of production and standard technologies that result in more flexible and cost-effective operations. The Multiplex model supports today’s reality of drugs with smaller target patient populations, uncertain market conditions and other factors.

“The companies that are adopting the Multiplex strategy are beating traditional supply chains in terms of cost of goods, time to market and quality,” says Chris Procyshyn, chief executive officer of Vanrx. “The pillars of the Multiplex are becoming a movement among the market leaders, so this is a must-read for executives looking to create a sustainable competitive advantage.”

Adopting a Multiplex strategy has a number of benefits, including:

  • Reduced time to market;
  • Maximizing the commercial potential of a multi-product portfolio;
  • Agility to respond to market changes; and
  • Effective and safe production of biologics for developing markets.

Vanrx was founded by experts in biopharmaceutical development and manufacturing. The company designs and manufactures Aseptic Filling Workcells—gloveless robotic isolators for producing vials, syringes and cartridges.

About Vanrx Pharmasystems

Vanrx Pharmasystems makes the most technologically advanced sterile filling solutions for the pharmaceutical industry. Vanrx fill-finish machines use isolated robotics and machine vision to automate the packaging of injectable drugs into nested vials, syringes, or cartridges. The company was founded by pharmaceutical industry veterans to create the systems needed to make the next generation of innovative therapies. For more information, visit

Contact Vanrx

To schedule interviews with Vanrx Pharmasystems CEO Chris Procyshyn or discuss future article contributions, please contact:

Eric Petz
Senior Marketing Manager
Vanrx Pharmasystems
Phone: +1.604.453.8660 ext. 773

Articles you may want to read

Infographic: Flexible aseptic filling is easier with Vanrx

Many companies are considering flexible aseptic filling machines as they build manufacturing capacity for new injectable therapies. The challenge is to make multiple products, delivered in a wider array of formats. Learn how Vanrx defines flexibility and why modularity does not equal flexibility.

Go to article

White paper: A New Paradigm for Manufacturing Injectable Medicines

Vanrx's white paper “A New Paradigm for Manufacturing Injectable Medicines” details a solution that supports the flexible production of parenteral drug products. This solution resolves long-standing issues in aseptic production, while enabling manufacturers to bring drug products to market faster.

Go to article